Jonathan Hyak

Dr. Jonathan Hyak

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
PHPaul Joseph Hampel
Paul Joseph Hampel
MSMahesh Swaminathan
Mahesh Swaminathan
KRKerry A. Rogers
Kerry A. Rogers
EPErin M. Parry
Erin M. Parry
JBJan A. Burger
Jan A. Burger
PTPhilip A. Thompson
Philip A. Thompson
Patients with chronic lymphocytic leukemia (CLL) who develop Richter transformation (RT) have a poor prognosis when treated with chemoimmunotherapy regimens used for de novo diffuse large B-cell lymphoma. Venetoclax, a BCL2 inhibitor, has single-agent efficacy in patients with RT and is potentially synergistic with chemoimmunotherapy. In this multicenter, retrospective study, we evaluated 62 patients with RT who received venetoclax-based treatment outside of a clinical trial, in combination with a Bruton tyrosine kinase inhibitor (BTKi; n=28), rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) (n=13), or intensive chemoimmunotherapy other than R-CHOP (n=21). The best overall and complete response rates were 36%/25%, 54%/46%, and 52%/38%, respectively. The median progression-free and overall survival estimates for the same treatment groups were 4.9/14.3 months, 14.9 months/not reached, and 3.3/9 months, respectively. CLL with del(17p) was associated with a lower complete response rate in the total cohort (odds ratio [OR] 0.15; 95% confidence interval [CI] 0.04-0.6; p=0.01) and venetoclax-naïve subgroup (OR 0.13; 95%CI 0.02-0.66; p=0.01). TP53 mutated CLL was associated with a lower complete response rate (OR 0.15; 95%CI 0.03-0.74; p=0.02) and shorter progression-free survival (hazard ratio 3.1; 95%CI 1.21-7.95; p=0.02) only in venetoclax-naïve subgroup. No other clinical or baseline characteristics, including prior venetoclax treatment for CLL, showed statistically significant association with outcomes. Grade 3-4 neutropenia and thrombocytopenia events were most frequent with intensive chemoimmunotherapy + venetoclax; grade 3-4 infection rates were similar across treatment groups. In this difficult-to-treat RT patient population, venetoclax-based combination regimens achieved high response rates, with durable remission and survival observed in a subset of patients.

1 September 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
JHJonathan Hyak
Jonathan Hyak
YHYing Huang
Ying Huang
KRKerry A. Rogers
Kerry A. Rogers
SBSeema A. Bhat
Seema A. Bhat
MGMichael Rhodes Grever
Michael Rhodes Grever
JWJennifer A. Woyach
Jennifer A. Woyach
Jonathan Mitry Hyak, Ying Huang, Kerry A. Rogers, Seema A Bhat, Michael Rhodes Grever, John C. Byrd, Adam S Kittai, Daniel Jones, Cecelia R Miller, Jennifer A.

23 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JHJonathan Hyak
Jonathan Hyak
SRSawsan Rashdan
Sawsan Rashdan
Central nervous system metastases involving the brain parenchyma and leptomeninges are common in non-small cell lung cancer, especially cases with EGFR mutations. Here, we examine treatment options for EGFR-mutated non-small cell lung cancer patients with central nervous system metastases, highlighting the efficacy of third-generation EGFR-targeted tyrosine kinase inhibitors. Furthermore, we examine the interplay of this modality with chemotherapy or radiation in resistant cases.

3 April 2023 in Hematological Oncology
Verified
Journal Article
Closed access
MAMatthew R. Avenarius
Matthew R. Avenarius
YHYing Huang
Ying Huang
JHJonathan Hyak
Jonathan Hyak
JBJohn C. Byrd
John C. Byrd
SBSeema A. Bhat
Seema A. Bhat
CMCecelia R. Miller
Cecelia R. Miller

28 July 2021 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
JHJonathan Hyak
Jonathan Hyak
MMMayar Al Mohajer
Mayar Al Mohajer
DMDaniel M. Musher
Daniel M. Musher
BMBenjamin L. Musher
Benjamin L. Musher
Objective: To investigate the relationship between the systemic inflammatory response syndrome (SIRS), early antibiotic use, and bacteremia in solid-tumor patients.Design, setting, and participants: We conducted a retrospective observational study of adults with solid tumors admitted to a tertiary-care hospital through the emergency department over a 2-year period. Patients with neutropenic fever, organ transplant, trauma, or cardiopulmonary arrest were excluded.Methods: Rates of SIRS, bacteremia, and early antibiotics (initiation within 8 hours of presentation) were compared using the χ2 and Student t tests. Binomial regression and receiver operator curves were analyzed to assess predictors of bacteremia and early antibiotics.Results: Early antibiotics were administered in 507 (37%) of 1,344 SIRS-positive cases and 492 (22%) of 2,236 SIRS-negative cases (P < .0001). Of SIRS-positive cases, 70% had blood cultures drawn within 48 hours and 19% were positive; among SIRS negative cases, 35% had cultures and 13% were positive (19% vs 13%; P = .003). Bacteremic cases were more often SIRS positive than nonbacteremic cases (60% vs 50%; P =.003), but they received early antibiotics at similar rates (50% vs 49%, P = .72). Three SIRS components predicted early antibiotics: temperature (OR, 1.7; 95% CI, 1.31–2.29; P = .0001), tachycardia (OR, 1.4; 95% CI, 1.10–1.69; P < .0001), and white blood-cell count (OR, 1.8; 95% CI, 1.56–2.14; P < .0001). Only temperature (OR, 1.6; 95% CI, 1.09–2.41; P = .01) and tachycardia (OR, 1.5; 95% CI, 1.09–2.06; P = .01) predicted bacteremia. SIRS criteria as a composite were poorly predictive of bacteremia (AUC, 0.57).Conclusions: SIRS criteria are frequently used to determine the need for early antibiotics, but they are poor predictors of bacteremia in solid-tumor patients. More reliable models are needed to guide judicious use of antibiotics in this population.